Free Trial
NASDAQ:RXST

RxSight Q2 2025 Earnings Report

RxSight logo
$8.00 -0.46 (-5.44%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$8.11 +0.11 (+1.39%)
As of 07/11/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RxSight EPS Results

Actual EPS
N/A
Consensus EPS
-$0.04
Beat/Miss
N/A
One Year Ago EPS
N/A

RxSight Revenue Results

Actual Revenue
N/A
Expected Revenue
$39.78 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

RxSight Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

RxSight Earnings Headlines

RxSight (NASDAQ:RXST) Earns Hold Rating from Jefferies Financial Group
Brokerages Set RxSight, Inc. (NASDAQ:RXST) PT at $30.20
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
RxSight, Inc. (RXST) Investors Who Lost Money - Morningstar
See More RxSight Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RxSight? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RxSight and other key companies, straight to your email.

About RxSight

RxSight (NASDAQ:RXST), a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

View RxSight Profile

More Earnings Resources from MarketBeat